Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback